NEW YORK (S&P Global Ratings) Nov. 17, 2020--S&P Global Ratings said today that Boston Scientific Corp.'s (BBB-/Stable/A-3) global voluntary recall of all unused inventory of the LOTUS Edge system and discontinuation of the LOTUS platform will not delay projected leverage reduction below 4x in 2021. LOTUS Edge accounts for less than 1% of Boston Scientific's revenue. It was on track to deliver approximately $75 million of revenue in 2020 and around $125 million in 2021. In addition, the company expects its decision to retire the LOTUS platform to be accretive to its 2021 earnings because of the product's low profitability, resulting from its limited scale and niche market position. Given the limited impact from the LOTUS recall and retirement, we
